home / stock / kprx / kprx articles
The Meaning Behind Value Stocks A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This...
What Defines a Value Stock? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's fut...
Shares of Skechers U.S.A., Inc. (NYSE: SKX) shares fell during Friday’s session after the company reported mixed fourth-quarter financial re...
Shares of C.H. Robinson Worldwide, Inc. (NASDAQ: CHRW) fell sharply during Thursday’s session after the company reported worse-than-expected ...
Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) shares are trading higher Thursday after the company announced a private placement of up to $45 million a...
Shares of Nextracker Inc. (NASDAQ: NXT) rose sharply during today’s pre-market trading after the company reported better-than-expected third...
What Defines a Value Stock? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's fut...
Understanding Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's futu...
News, Short Squeeze, Breakout and More Instantly...
Kiora Pharmaceuticals Inc. Company Name:
KPRX Stock Symbol:
NASDAQ Market:
Phoenix, Arizona and New York, New York--(Newsfile Corp. - May 29, 2024) - Lytham Partners, a leading investor relations and corporate access firm, today announced the schedule for its Spring 2024 Investor Conference taking place virtually on May 30, 2024. More than 40 companies will be available...
Encinitas, California--(Newsfile Corp. - May 20, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (KPRX) ("Kiora" or the "Company"), will participate in two upcoming investor conferences that will be available to investors live with the replay available on-demand. On Wednesday May 22, at 3:00...
Phase 2 trial for KIO-301 for the treatment of retinitis pigmentosa, in partnership with Théa Open Innovation, expected to be initiated in Q4 2024 Phase 2 clinical trial for KIO-104 for retinal inflammation expected to begin in 2025 Ended Q1 2024 with $31.3 million in cash and cash eq...